nach oben

Cancer and Metastasis Reviews

Erschienen in:

11.04.2016 | NON-THEMATIC REVIEW

Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology

verfasst von: Raghuveera Kumar Goel, Kiven Erique Lukong

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The non-receptor tyrosine kinase Fyn-related kinase (FRK) is a member of the BRK family kinases (BFKs) and is distantly related to the Src family kinases (SFKs). FRK was first discovered in 1993, and studies pursued thereafter attributed a potential tumour-suppressive function to the enzyme. In recent years, however, further functional characterization of the tyrosine kinase in diverse cancer types suggests that FRK may potentially play an oncogenic role as well. Specifically, while ectopic expression of FRK suppresses cell proliferation and migration in breast and brain cancers, knockdown or catalytic inhibition of FRK suppresses these cellular processes in pancreatic and liver cancer. Such functional paradox is therefore evidently exhibited in a tissue-specific context. This review sheds light on the recent developments emerged from investigations on FRK which include: (a) a review of the expression pattern of the protein in mammalian cells/tissues, (b) underlying genomic perturbations and (c) a mechanistic function of the enzyme across different cellular environments. Given its functional heterogeneity observed across different cancers, we also discuss the therapeutic significance of FRK.

Goel, R. K., & Lukong, K. E. (2015). Tracing the footprints of the breast cancer oncogene BRK—past till present. Biochimica et biophysica acta, 1856, 39–54.PubMed

Cance, W. G., Craven, R. J., Weiner, T. M., & Liu, E. T. (1993). Novel protein kinases expressed in human breast cancer, International journal of cancer. Journal international du cancer, 54, 571–577.CrossRefPubMed

Cance, W. G., Craven, R. J., Bergman, M., Xu, L., Alitalo, K., & Liu, E. T. (1994). Rak, a novel nuclear tyrosine kinase expressed in epithelial cells. Cell growth & differentiation, 5, 1347–1355.

Lee, J., Wang, Z., Luoh, S. M., Wood, W. I., & Scadden, D. T. (1994). Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene. Gene, 138, 247–251.CrossRefPubMed

Brauer, P. M., & Tyner, A. L. (2009). RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell Cycle, 8, 2728–2732.CrossRefPubMedPubMedCentral

Sheng, Z. M., Marchetti, A., Buttitta, F., Champeme, M. H., Campani, D., Bistocchi, M., Lidereau, R., & Callahan, R. (1996). Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. British journal of cancer, 73, 144–147.CrossRefPubMedPubMedCentral

Becher, R., Gibas, Z., Karakousis, C., & Sandberg, A. A. (1983). Nonrandom chromosome changes in malignant melanoma. Cancer research, 43, 5010–5016.PubMed

Becher, R., Gibas, Z., & Sandberg, A. A. (1983). Chromosome 6 in malignant melanoma. Cancer genetics and cytogenetics, 9, 173–175.CrossRefPubMed

Girard, L., Zochbauer-Muller, S., Virmani, A. K., Gazdar, A. F., & Minna, J. D. (2000). Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer research, 60, 4894–4906.PubMed

10.

Oberg-Welsh, C., & Welsh, M. (1995). Cloning of BSK, a murine FRK homologue with a specific pattern of tissue distribution. Gene, 152, 239–242.CrossRefPubMed

11.

Thuveson, M., Albrecht, D., Zurcher, G., Andres, A. C., & Ziemiecki, A. (1995). iyk, a novel intracellular protein tyrosine kinase differentially expressed in the mouse mammary gland and intestine. Biochemical and biophysical research communications, 209, 582–589.CrossRefPubMed

12.

Sunitha, I., & Avigan, M. I. (1994). A newly identified tyrosine kinase is preferentially expressed in the gastrointestinal tract. Biochimica et biophysica acta, 1221, 348–352.CrossRefPubMed

13.

Sunitha, I., & Avigan, M. I. (1996). The apical membranes of maturing gut columnar epithelial cells contain the enzymatically active form of a newly identified fyn-related tyrosine kinase. Oncogene, 13, 547–559.PubMed

14.

Oberg-Welsh, C., Anneren, C., & Welsh, M. (1998). Mutation of C-terminal tyrosine residues Y497/Y504 of the Src-family member Bsk/Iyk decreases NIH3T3 cell proliferation. Growth Factors, 16, 111–124.CrossRefPubMed

15.

Anneren, C., & Welsh, M. (2000). Role of the Bsk/Iyk non-receptor tyrosine kinase for the control of growth and hormone production in RINm5F cells. Growth Factors, 17, 233–247.CrossRefPubMed

16.

Okada, M., & Nakagawa, H. (1989). A protein tyrosine kinase involved in regulation of pp60c-src function. The Journal of Biological Chemistry, 264, 20886–20893.PubMed

17.

Nada, S., Okada, M., MacAuley, A., Cooper, J. A., & Nakagawa, H. (1991). Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature, 351, 69–72.CrossRefPubMed

18.

Partanen, J., Armstrong, E., Bergman, M., Makela, T. P., Hirvonen, H., Huebner, K., & Alitalo, K. (1991). cyl encodes a putative cytoplasmic tyrosine kinase lacking the conserved tyrosine autophosphorylation site (Y416src). Oncogene, 6, 2013–2018.PubMed

19.

Sabe, H., Knudsen, B., Okada, M., Nada, S., Nakagawa, H., & Hanafusa, H. (1992). Molecular cloning and expression of chicken C-terminal Src kinase: lack of stable association with c-Src protein. Proceedings of the National Academy of Sciences of the United States of America, 89, 2190–2194.CrossRefPubMedPubMedCentral

20.

Okada, M., Nada, S., Yamanashi, Y., Yamamoto, T., & Nakagawa, H. (1991). CSK: a protein-tyrosine kinase involved in regulation of src family kinases. The Journal of Biological Chemistry, 266, 24249–24252.PubMed

21.

Meyer, T., Xu, L., Chang, J., Liu, E. T., Craven, R. J., & Cance, W. G. (2003). Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase, International journal of cancer. Journal international du cancer, 104, 139–146.CrossRefPubMed

22.

Qiu, H., & Miller, W. T. (2004). Role of the Brk SH3 domain in substrate recognition. Oncogene, 23, 2216–2223.CrossRefPubMed

23.

Snyder, M. A., Bishop, J. M., McGrath, J. P., & Levinson, A. D. (1985). A mutation at the ATP-binding site of pp60v-src abolishes kinase activity, transformation, and tumorigenicity. Molecular and cellular biology, 5, 1772–1779.CrossRefPubMedPubMedCentral

24.

Goel, R. K., Miah, S., Black, K., Kalra, N., Dai, C., & Lukong, K. E. (2013). The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1. The FEBS journal, 280, 4539–4559.CrossRefPubMed

25.

McPherson, R. A., Taylor, M. M., Hershey, E. D., & Sturgill, T. W. (2000). A different function for a critical tryptophan in c-Raf and Hck. Oncogene, 19, 3616–3622.CrossRefPubMed

26.

Berclaz, G., Altermatt, H. J., Rohrbach, V., Dreher, E., Ziemiecki, A., & Andres, A. C. (2000). Hormone-dependent nuclear localization of the tyrosine kinase iyk in the normal human breast epithelium and loss of expression during carcinogenesis, International journal of cancer. Journal international du cancer, 85, 889–894.CrossRefPubMed

27.

Serfas, M. S., & Tyner, A. L. (2003). Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncology research, 13, 409–419.CrossRefPubMed

28.

L. Jin, R.J. Craven. (2013). The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor. Oncogene.

29.

Ie Kim, H., & Lee, S. T. (2009). Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. Journal of biochemistry, 146, 133–139.CrossRefPubMed

30.

Brauer, P. M., Zheng, Y., Wang, L., & Tyner, A. L. (2010). Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells. Cell Cycle, 9, 4190–4199.CrossRefPubMedPubMedCentral

31.

Peng, M., Emmadi, R., Wang, Z., Wiley, E. L., Gann, P. H., Khan, S. A., Banerji, N., McDonald, W., Asztalos, S., Pham, T. N., Tonetti, D. A., & Tyner, A. L. (2014). PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget, 5, 6038–6048.CrossRefPubMedPubMedCentral

32.

Zhou, X., Hua, L., Zhang, W., Zhu, M., Shi, Q., Li, F., Zhang, L., Song, C., & Yu, R. (2012). FRK controls migration and invasion of human glioma cells by regulating JNK/c-Jun signaling. Journal of neuro-oncology, 110, 9–19.CrossRefPubMed

33.

Hua, L., Zhu, M., Song, X., Wang, J., Fang, Z., Zhang, C., Shi, Q., Zhan, W., Wang, L., Meng, Q., Zhou, X., & Yu, R. (2014). FRK suppresses the proliferation of human glioma cells by inhibiting cyclin D1 nuclear accumulation. Journal of neuro-oncology, 119, 49–58.CrossRefPubMed

34.

Zhao, B., Tan, P. H., Li, S. S., & Pei, D. (2013). Systematic characterization of the specificity of the SH2 domains of cytoplasmic tyrosine kinases. Journal of proteomics, 81, 56–69.CrossRefPubMed

35.

Yim, E. K., Peng, G., Dai, H., Hu, R., Li, K., Lu, Y., Mills, G. B., Meric-Bernstam, F., Hennessy, B. T., Craven, R. J., & Lin, S. Y. (2009). Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell, 15, 304–314.CrossRefPubMedPubMedCentral

36.

Craven, R. J., Cance, W. G., & Liu, E. T. (1995). The nuclear tyrosine kinase Rak associates with the retinoblastoma protein pRb. Cancer research, 55, 3969–3972.PubMed

37.

Benedict, W. F., Murphree, A. L., Banerjee, A., Spina, C. A., Sparkes, M. C., & Sparkes, R. S. (1983). Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science, 219, 973–975.CrossRefPubMed

38.

Weinberg, R. A. (1995). The retinoblastoma protein and cell cycle control. Cell, 81, 323–330.CrossRefPubMed

39.

Welch, P. J., & Wang, J. Y. (1993). A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell, 75, 779–790.CrossRefPubMed

40.

Yim, E. K., Siwko, S., & Lin, S. Y. (2009). Exploring Rak tyrosine kinase function in breast cancer. Cell Cycle, 8, 2360–2364.CrossRefPubMed

41.

J.L. Kim, G.H. Ha, L. Campo, M.F. Denning, T.B. Patel, C. Osipo, S.Y. Lin, E.K. Breuer. (2015). The role of Rak in the regulation of stability and function of BRCA1. Oncotarget.

42.

Yoshida, K., & Miki, Y. (2004). Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer science, 95, 866–871.CrossRefPubMed

43.

Bougie, O., & Weberpals, J. I. (2011). Clinical considerations of BRCA1- and BRCA2-mutation carriers: a review. International journal of surgical oncology, 2011, 374012.CrossRefPubMedPubMedCentral

44.

Pendergast, A. M. (1996). Nuclear tyrosine kinases: from Abl to WEE1. Current opinion in cell biology, 8, 174–181.CrossRefPubMed

45.

Berthet, C., & Kaldis, P. (2006). Cdk2 and Cdk4 cooperatively control the expression of Cdc2. Cell division, 1, 10.CrossRefPubMedPubMedCentral

46.

Anneren, C., Reedquist, K. A., Bos, J. L., & Welsh, M. (2000). GTK, a Src-related tyrosine kinase, induces nerve growth factor-independent neurite outgrowth in PC12 cells through activation of the Rap1 pathway. Relationship to Shb tyrosine phosphorylation and elevated levels of focal adhesion kinase. The Journal of Biological Chemistry, 275, 29153–29161.CrossRefPubMed

47.

Anneren, C., & Welsh, M. (2002). GTK tyrosine kinase-induced alteration of IRS-protein signalling in insulin producing cells. Molecular Medicine, 8, 705–713.PubMedPubMedCentral

48.

Anneren, C., Lindholm, C. K., Kriz, V., & Welsh, M. (2003). The FRK/RAK-SHB signaling cascade: a versatile signal-transduction pathway that regulates cell survival, differentiation and proliferation. Current molecular medicine, 3, 313–324.CrossRefPubMed

49.

Chen, J. S., Hung, W. S., Chan, H. H., Tsai, S. J., & Sun, H. S. (2013). In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma. Bioinformatics, 29, 420–427.CrossRefPubMed

50.

Je, D. W., YM, O., Ji, Y. G., Cho, Y., & Lee, D. H. (2014). The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Pancreas, 43, 768–776.CrossRefPubMed

51.

Tan, A. C., Jimeno, A., Lin, S. H., Wheelhouse, J., Chan, F., Solomon, A., Rajeshkumar, N. V., Rubio-Viqueira, B., & Hidalgo, M. (2009). Characterizing DNA methylation patterns in pancreatic cancer genome. Molecular oncology, 3, 425–438.CrossRefPubMed

52.

Klijn, C., Durinck, S., Stawiski, E. W., Haverty, P. M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., Pau, G., Reeder, J., Cao, Y., Mukhyala, K., Selvaraj, S. K., Yu, M., Zynda, G. J., Brauer, M. J., Wu, T. D., Gentleman, R. C., Manning, G., Yauch, R. L., Bourgon, R., Stokoe, D., Modrusan, Z., Neve, R. M., de Sauvage, F. J., Settleman, J., Seshagiri, S., & Zhang, Z. (2015). A comprehensive transcriptional portrait of human cancer cell lines. Nature biotechnology, 33, 306–312.CrossRefPubMed

53.

Hosoya, N., Qiao, Y., Hangaishi, A., Wang, L., Nannya, Y., Sanada, M., Kurokawa, M., Chiba, S., Hirai, H., & Ogawa, S. (2005). Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. Genes, chromosomes & cancer, 42, 269–279.CrossRef

54.

Pilati, C., Letouze, E., Nault, J. C., Imbeaud, S., Boulai, A., Calderaro, J., Poussin, K., Franconi, A., Couchy, G., Morcrette, G., Mallet, M., Taouji, S., Balabaud, C., Terris, B., Canal, F., Paradis, V., Scoazec, J. Y., de Muret, A., Guettier, C., Bioulac-Sage, P., Chevet, E., Calvo, F., & Zucman-Rossi, J. (2014). Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell, 25, 428–441.CrossRefPubMed

55.

Knowlton, M. L., Selfors, L. M., Wrobel, C. N., Gu, T. L., Ballif, B. A., Gygi, S. P., Polakiewicz, R., & Brugge, J. S. (2010). Profiling Y561-dependent and -independent substrates of CSF-1R in epithelial cells. PloS one, 5, e13587.CrossRefPubMedPubMedCentral

56.

Sunitha, I., Shen, R., McKillop, I. H., Lee, J. H., Resau, J., & Avigan, M. (1999). A src-related kinase in the brush border membranes of gastrointestinal cells is regulated by c-met. Experimental cell research, 250, 86–98.CrossRefPubMed

57.

Palka-Hamblin, H. L., Gierut, J. J., Bie, W., Brauer, P. M., Zheng, Y., Asara, J. M., & Tyner, A. L. (2010). Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. Journal of Cell Science, 123, 236–245.CrossRefPubMed

58.

Shi, Q., Song, X., Wang, J., Gu, J., Zhang, W., Hu, J., Zhou, X., & Yu, R. (2015). FRK inhibits migration and invasion of human glioma cells by promoting N-cadherin/beta-catenin complex formation. Journal of molecular neuroscience, 55, 32–41.CrossRefPubMed

59.

Camand, E., Peglion, F., Osmani, N., Sanson, M., & Etienne-Manneville, S. (2012). N-cadherin expression level modulates integrin-mediated polarity and strongly impacts on the speed and directionality of glial cell migration. Journal of Cell Science, 125, 844–857.CrossRefPubMed

60.

Zhang, X., Liu, G., Kang, Y., Dong, Z., Qian, Q., & Ma, X. (2013). N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PloS one, 8, e57692.CrossRefPubMedPubMedCentral

61.

Wang, J. L., Chen, Z. F., Chen, H. M., Wang, M. Y., Kong, X., Wang, Y. C., Sun, T. T., Hong, J., Zou, W., Xu, J., & Fang, J. Y. (2014). Elf3 drives beta-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell death & disease, 5, e1263.CrossRef

62.

Kwon, Y. T., Gupta, A., Zhou, Y., Nikolic, M., & Tsai, L. H. (2000). Regulation of N-cadherin-mediated adhesion by the p35-Cdk5 kinase. Current biology, 10, 363–372.CrossRefPubMed

63.

Bhargava, R., Gerald, W. L., Li, A. R., Pan, Q., Lal, P., Ladanyi, M., & Chen, B. (2005). EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern pathology, 18, 1027–1033.CrossRefPubMed

64.

Rimawi, M. F., Shetty, P. B., Weiss, H. L., Schiff, R., Osborne, C. K., Chamness, G. C., & Elledge, R. M. (2010). Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer, 116, 1234–1242.CrossRefPubMedPubMedCentral

65.

Sun, B., Yang, N., Jiang, Y., Zhang, H., Hou, C., Ji, C., Liu, Y., & Zuo, P. (2015). Antagomir-1290 suppresses CD133(+) cells in non-small cell lung cancer by targeting fyn-related Src family tyrosine kinase. Tumour biology, 36, 6223–6230.CrossRefPubMed

66.

Varnholt, H., Drebber, U., Schulze, F., Wedemeyer, I., Schirmacher, P., Dienes, H. P., & Odenthal, M. (2008). MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology, 47, 1223–1232.CrossRefPubMed

67.

Shukla, S., Shishodia, G., Mahata, S., Hedau, S., Pandey, A., Bhambhani, S., Batra, S., Basir, S. F., Das, B. C., & Bharti, A. C. (2010). Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Molecular cancer, 9, 282.CrossRefPubMedPubMedCentral

68.

Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A., & Jove, R. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene, 20, 2499–2513.CrossRefPubMed

69.

Azare, J., Leslie, K., Al-Ahmadie, H., Gerald, W., Weinreb, P. H., Violette, S. M., & Bromberg, J. (2007). Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Molecular and cellular biology, 27, 4444–4453.CrossRefPubMedPubMedCentral

70.

Welsh, M., Welsh, C., Ekman, M., Dixelius, J., Hagerkvist, R., Anneren, C., Akerblom, B., Mahboobi, S., Chandrasekharan, S., & Liu, E. T. (2004). The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity. The Biochemical journal, 382, 261–268.CrossRefPubMedPubMedCentral

71.

Chandrasekharan, S., Qiu, T. H., Alkharouf, N., Brantley, K., Mitchell, J. B., & Liu, E. T. (2002). Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak. Molecular and cellular biology, 22, 5235–5247.CrossRefPubMedPubMedCentral

72.

Akerblom, B., Anneren, C., & Welsh, M. (2007). A role of FRK in regulation of embryonal pancreatic beta cell formation. Molecular and cellular endocrinology, 270, 73–78.CrossRefPubMed

73.

Anneren, C., & Welsh, M. (2001). Increased cytokine-induced cytotoxicity of pancreatic islet cells from transgenic mice expressing the Src-like tyrosine kinase GTK. Molecular Medicine, 7, 301–310.PubMedPubMedCentral

74.

Anneren, C. (2002). Dual role of the tyrosine kinase GTK and the adaptor protein SHB in beta-cell growth: enhanced beta-cell replication after 60% pancreatectomy and increased sensitivity to streptozotocin. The Journal of endocrinology, 172, 145–153.CrossRefPubMed

75.

Anneren, C., Welsh, M., & Jansson, L. (2007). Glucose intolerance and reduced islet blood flow in transgenic mice expressing the FRK tyrosine kinase under the control of the rat insulin promoter, American journal of physiology. Endocrinology and metabolism, 292, E1183–1190.PubMed

76.

Roe, K., Bratland, A., Vlatkovic, L., Ragnum, H. B., Saelen, M. G., Olsen, D. R., Marignol, L., & Ree, A. H. (2013). Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer. PloS one, 8, e63723.CrossRefPubMedPubMedCentral

77.

Cowin, P. A., Anglesio, M., Etemadmoghadam, D., & Bowtell, D. D. (2010). Profiling the cancer genome. Annual review of genomics and human genetics, 11, 133–159.CrossRefPubMed

78.

Son, J. W., Jeong, K. J., Jean, W. S., Park, S. Y., Jheon, S., Cho, H. M., Park, C. G., Lee, H. Y., & Kang, J. (2011). Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients. Cancer letters, 311, 29–37.CrossRefPubMed

79.

Park, J. J., Kang, J. K., Hong, S., Ryu, E. S., Kim, J. I., Lee, J. H., & Seo, J. S. (2008). Genome-wide combination profiling of copy number and methylation offers an approach for deciphering misregulation and development in cancer cells. Gene, 407, 139–147.CrossRefPubMed

80.

Kleivi, K., Lothe, R. A., Heim, S., Tsarouha, H., Kraggerud, S. M., Pandis, N., Papadopoulou, A., Andersen, J., Jakobsen, K. S., & Teixeira, M. R. (2002). Genome profiling of breast cancer cells selected against in vitro shows copy number changes. Genes, chromosomes & cancer, 33, 304–309.CrossRef

81.

Kashiwagi, H., & Uchida, K. (2000). Genome-wide profiling of gene amplification and deletion in cancer. Human cell, 13, 135–141.PubMed

82.

Chen, Y., Hao, J., Jiang, W., He, T., Zhang, X., Jiang, T., & Jiang, R. (2013). Identifying potential cancer driver genes by genomic data integration. Scientific reports, 3, 3538.PubMedPubMedCentral

83.

Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009). The cancer genome. Nature, 458, 719–724.CrossRefPubMedPubMedCentral

84.

Jin, G., Jeon, H. S., Yang, E., & Park, J. Y. (2011). Mutation analysis of the FRK gene in non-small cell lung cancers. Lung Cancer, 71, 115–117.CrossRefPubMed

85.

Grebien, F., Hantschel, O., Wojcik, J., Kaupe, I., Kovacic, B., Wyrzucki, A. M., Gish, G. D., Cerny-Reiterer, S., Koide, A., Beug, H., Pawson, T., Valent, P., Koide, S., & Superti-Furga, G. (2011). Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell, 147, 306–319.CrossRefPubMedPubMedCentral

86.

Brauer, P. M., & Tyner, A. L. (2010). Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochimica et Biophysica Acta, 1806, 66–73.PubMedPubMedCentral

87.

Y. Zheng, J. Gierut, Z. Wang, J. Miao, J.M. Asara, A.L. Tyner. (2012). Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene.

88.

Zheng, Y., & Tyner, A. L. (2013). Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer. European journal of clinical investigation, 43, 397–404.CrossRefPubMedPubMedCentral

89.

Haegebarth, A., Bie, W., Yang, R., Crawford, S. E., Vasioukhin, V., Fuchs, E., & Tyner, A. L. (2006). Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Molecular and cellular biology, 26, 4949–4957.CrossRefPubMedPubMedCentral

90.

Ma, S., Bao, J. Y., Kwan, P. S., Chan, Y. P., Tong, C. M., Fu, L., Zhang, N., Tong, A. H., Qin, Y. R., Tsao, S. W., Chan, K. W., Lok, S., & Guan, X. Y. (2012). Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology, 143, 675–686. e671-612.CrossRefPubMed

91.

Liu, X. K., Zhang, X. R., Zhong, Q., Li, M. Z., Liu, Z. M., Lin, Z. R., Wu, D., & Zeng, M. S. (2013). Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma. Journal of translational medicine, 11, 59.CrossRefPubMedPubMedCentral

92.

Li, X., Lu, Y., Liang, K., Hsu, J. M., Albarracin, C., Mills, G. B., Hung, M. C., & Fan, Z. (2012). Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene, 31, 4372–4383.CrossRefPubMedPubMedCentral

93.

Xiang, B., Chatti, K., Qiu, H., Lakshmi, B., Krasnitz, A., Hicks, J., Yu, M., Miller, W. T., & Muthuswamy, S. K. (2008). Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 105, 12463–12468.CrossRefPubMedPubMedCentral

94.

Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S., Superti-Furga, G., Koomen, J., & Haura, E. B. (2010). A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature chemical biology, 6, 291–299.CrossRefPubMedPubMedCentral

95.

Montero, J. C., Seoane, S., Ocana, A., & Pandiella, A. (2011). Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clinical cancer research, 17, 5546–5552.CrossRefPubMed

Titel: Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology
verfasst von: Raghuveera Kumar Goel
Kiven Erique Lukong
Publikationsdatum: 11.04.2016
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2/2016
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-016-9623-3

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

The promising alliance of anti-cancer electrochemotherapy with immunotherapy

Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer

Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?

The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie